Myocardial Infarction Therapeutics Report, H1 2019 – Pipeline Review of 50 Companies & Drug Profiles – ResearchAndMarkets.com

Infarction – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Myocardial Infarction – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Myocardial
Infarction (Cardiovascular), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews
of key players involved in therapeutic development for Myocardial
Infarction and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase
II, Phase I, Preclinical, Discovery and Unknown stages are 5, 15, 8, 53,
7 and 1 respectively. Similarly, the Universities portfolio in Phase II,
Preclinical and Discovery stages comprises 3, 20 and 4 molecules,

Myocardial Infarction (Cardiovascular) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.


  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial
    Infarction (Cardiovascular) by companies and universities/research
    institutes based on information derived from company and
    industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
  • The pipeline guide reviews key companies involved in Myocardial
    Infarction (Cardiovascular) therapeutics and enlists all their major
    and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Myocardial Infarction (Cardiovascular) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Actinogen Medical Ltd
  • Angion Biomedica Corp
  • Applied Therapeutics Inc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Bharat Biotech Ltd
  • BioCardia Inc
  • Biscayne Pharmaceuticals Inc
  • Cadila Healthcare Ltd
  • Cardiol Therapeutics Inc
  • Celixir Ltd
  • CellProthera SAS
  • CFM Pharma Holding BV
  • Cynata Therapeutics Ltd
  • Diffusion Pharmaceuticals Inc
  • Evotec AG
  • EyeGene Inc
  • Faraday Pharmaceuticals Inc
  • Hemostemix Inc
  • HUYA Bioscience International LLC
  • Idorsia Pharmaceutical Ltd
  • InCarda Therapeutics Inc
  • Inotrem SA
  • K-Stemcell Co Ltd
  • Laboratoires Pierre Fabre SA
  • Lee’s Pharmaceutical Holdings Ltd
  • LG Chem Ltd
  • Lonestar Heart Inc
  • Mesoblast Ltd
  • MimeTech Srl
  • New World Laboratories Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • OMEICOS Therapeutics GmbH
  • Opsona Therapeutics Ltd
  • Otsuka Holdings Co Ltd
  • Quark Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Recardio GmbH
  • Reliance Life Sciences Pvt Ltd
  • Rubicon Biotechnology Inc
  • Silver Creek Pharmaceuticals Inc
  • TaiGen Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Thrombolytic Science International LLC
  • Vicore Pharma AB
  • ViroMed Co Ltd
  • XBiotech Inc
  • YiChang Humanwell Pharmaceutical Co Ltd
  • Yuyu Pharma Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qcxxfq/myocardial?w=4


Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Cardiovascular

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.